Bifractionated CPT-11 With LV5FU2 Infusion (FOLFIRI-3) in Combination With Bevacizumab: Clinical Outcomes in First-Line Metastatic Colorectal Cancers According to Plasma Angiopoietin-2 Levels

BMC Cancer - United Kingdom
doi 10.1186/1471-2407-13-611
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Phase 2 Randomised Study of Veliparib Plus FOLFIRI±bevacizumab Versus Placebo Plus FOLFIRI±bevacizumab in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Reply: Capecitabine and Bevacizumab as First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2010English

Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation

OncoTargets and Therapy
OncologyPharmacology
2013English

Impact of Tumour RAS/BRAF Status in a First-Line Study of Panitumumab + FOLFIRI in Patients With Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2016English

FOLFIRI® and Bevacizumab in First-Line Treatment for Colorectal Cancer Patients: Safety, Efficacy and Genetic Polymorphisms

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2014English

A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-Line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Angiopoietin-2 Levels Are Associated With Disease Progression in Metastatic Malignant Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2009English

Discontinuation of First-Line Bevacizumab in Metastatic Colorectal Cancer: The BEAWARE Italian Observational Study

Tumori
MedicineCancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy